AstraZeneca. “The results from these Phase 3 trials support the clinical benefit of PT027, an albuterol/budesonide rescue inhaler, which has the potential to be a first-in-class treatment ...

Following this approval, AstraZeneca has the option ... Current albuterol rescue inhalers alleviate acute symptoms, but do not treat the underlying inflammation in asthma.” ...

Airsupra is the first FDA-approved rescue medication ... with these AstraZeneca devices enables real-time data collection and insights into medication usage and inhaler technique.

AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, the drugmaker announced Monday. The Britain based pharma giant said the expanded ...

AstraZeneca recently announced the completion of clinical studies for a next-generation propellant (NGP) version of its chronic obstructive pulmonary disease (COPD) inhaler, Breztri. This new ...